Pharmaceutical Innovation

作者: Frank A. Sloan 著 , Frank A. 编 , Chee-Ruey Hsieh 编

出版社: Cambridge University Press

出版时间: 2007-04

版次: 1

ISBN: 9780521874908

定价: 519.70

装帧: 精装

开本: 16开

纸张: 胶版纸

页数: 346页

正文语种: 英语

分类: 外文古旧书>英文书>管理

Thepharmaceuticalindustryworldwideisarapidlyburgeoningindustrycontributingtogrowthofgrossdomesticproductandemployment.Technologicalchangeinthisfieldhasbeenveryrapid,withmanynewproductsbeingintroduced.Forthisreasoninpart,healthcarebudgetsthroughouttheworldhaveincreaseddramatically,elicitinggrowingpressuresforcostcontainment.Thisbookexploresfourimportantissuesinpharmaceuticalinnovations:(1)theindustrystructureofpharmaceuticalinnovation;(2)incentivesforcorrectingmarketfailuresinallocatingresourcesforresearchanddevelopment;(3)competitionandmarketing;and(4)publicevaluationofthebenefitsandcostsofinnovation.Thelessonsareapplicabletocountriesallovertheworld,atalllevelsofeconomicdevelopment.Bydiscussingexistingevidencethisbookproposesincentivearrangementstoaccomplishsocialobjectives. FrankSloanhasbeentheJ.AlexanderMcMahonProfessorofHealthPolicyandManagementandProfessorofEconomicsatDukeUniversitysince1993,whereheholdsfacultyappointmentsintheDepartmentofEconomics,theSchoolofPublicPolicy,theFuquaSc List of Tables

List of Figures

Contributors

Acknowledgments

1. Introduction

PART I.  THE INDUSTRY STRUCTURE OF PHARMACEUTICAL INNOVATION

　2. The Pharmaceutical Sector in Health Care

　3. The Economics of Research and Development in the Pharmaceutical Industry

PART 1I. STRUCTURING INCENTIVES FOR RESEARCH AND DEVELOPMENT

  4. Drugs for Neglected Diseases: New Incentives for Innovation

  5. When Patents Fail: Finding New Drugs for the Developing World

  6. Implementing a Public Subsidy for Vaccines

　7.  Ensuring the Future Supply of Vaccines: Is a National Vaccine Authority the Answer?

PART III. COMPETITION AND MARKETING

　8.  Competition between Generic and Branded Drugs

　9.  The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned?

PART IV. PUBLIC EVALUATION OF THE BENEFITS AND COSTS OF INNOVATION

　10.  Measures of Costs and Benefits for Drugs in Cost-Effectiveness Analysis

　11.  Using Economic Evaluation in Reimbursement Decisions for Health Technologies: Lessons from International Experience

　12.  Pharmaceutical Spending and Health Outcomes

　13.  Pharmaceutical Innovation and Health Outcomes: Empirical Evidence from Taiwan

　14.  Conclusions and Policy Implications

Notes

References

lndex
内容简介:
Thepharmaceuticalindustryworldwideisarapidlyburgeoningindustrycontributingtogrowthofgrossdomesticproductandemployment.Technologicalchangeinthisfieldhasbeenveryrapid,withmanynewproductsbeingintroduced.Forthisreasoninpart,healthcarebudgetsthroughouttheworldhaveincreaseddramatically,elicitinggrowingpressuresforcostcontainment.Thisbookexploresfourimportantissuesinpharmaceuticalinnovations:(1)theindustrystructureofpharmaceuticalinnovation;(2)incentivesforcorrectingmarketfailuresinallocatingresourcesforresearchanddevelopment;(3)competitionandmarketing;and(4)publicevaluationofthebenefitsandcostsofinnovation.Thelessonsareapplicabletocountriesallovertheworld,atalllevelsofeconomicdevelopment.Bydiscussingexistingevidencethisbookproposesincentivearrangementstoaccomplishsocialobjectives.
作者简介:
FrankSloanhasbeentheJ.AlexanderMcMahonProfessorofHealthPolicyandManagementandProfessorofEconomicsatDukeUniversitysince1993,whereheholdsfacultyappointmentsintheDepartmentofEconomics,theSchoolofPublicPolicy,theFuquaSc
目录:
List of Tables

List of Figures

Contributors

Acknowledgments

1. Introduction

PART I.  THE INDUSTRY STRUCTURE OF PHARMACEUTICAL INNOVATION

　2. The Pharmaceutical Sector in Health Care

　3. The Economics of Research and Development in the Pharmaceutical Industry

PART 1I. STRUCTURING INCENTIVES FOR RESEARCH AND DEVELOPMENT

  4. Drugs for Neglected Diseases: New Incentives for Innovation

  5. When Patents Fail: Finding New Drugs for the Developing World

  6. Implementing a Public Subsidy for Vaccines

　7.  Ensuring the Future Supply of Vaccines: Is a National Vaccine Authority the Answer?

PART III. COMPETITION AND MARKETING

　8.  Competition between Generic and Branded Drugs

　9.  The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned?

PART IV. PUBLIC EVALUATION OF THE BENEFITS AND COSTS OF INNOVATION

　10.  Measures of Costs and Benefits for Drugs in Cost-Effectiveness Analysis

　11.  Using Economic Evaluation in Reimbursement Decisions for Health Technologies: Lessons from International Experience

　12.  Pharmaceutical Spending and Health Outcomes

　13.  Pharmaceutical Innovation and Health Outcomes: Empirical Evidence from Taiwan

　14.  Conclusions and Policy Implications

Notes

References

lndex

查看详情

Pharmaceutical Innovation

内容简介:

作者简介:

目录: